TMPRSS2 and COVID-19: Among the drugs that strongly inhibit TMPRSS2, nafamostat mesylate has the strongest antiviral effect against COVID-19, and its IC50 value is approximately 600 times higher than that of remdesivir, the standard treatment for COVID-19 [12].